The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure
Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
SGLT2 inhibitor is a new type of sugar-lowering medicine and is recommended to treat heart
failure. eGFR lower than 30ml/min/1.73M2 is contraindication of SGLT2 inhibitor. Heart
failure is one of the most frequency CVD events for hemodialysis patients. But hemodialysis
patient is unable to be treated with SGLT2 inhibitors as the contraindication. However,
solute and fluid clearance are dependent on dialysis, but not renal function in hemodialysis
patients. There is no data of SGLT2 inhibitor on hemodialysis patients. The aim of the
present study is evaluate the safety of Dapagliflozin in hemodialysis patients with heart
failure.
This is a randomized, control, open study. 20 hemodialysis patients with heart failure will
be recruited. 10 of 20 subjects will be treated with dapagliflozin 10mg everyday for 12
weeks. The primary outcome is a composite of numbers of hypoglycemia events, urinary
infection events and abnormal of laboratory results. The secondary outcomes is the changes of
NT-.